Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma

Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Devyn Taylor Coskey(Memorial Sloan Kettering Cancer Center), Joseph Vijai(Memorial Sloan Kettering Cancer Center), Ozge Ceyhan‐Birsoy(Memorial Sloan Kettering Cancer Center), Angela G. Arnold(Memorial Sloan Kettering Cancer Center), Nisha Pradhan(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), Michael F. Walsh(Memorial Sloan Kettering Cancer Center), Andrea Knežević(Memorial Sloan Kettering Cancer Center), Yelena Kemel(Kettering University), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Karen A. Cadoo(Trinity College Dublin), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Diana Mandelker(Memorial Sloan Kettering Cancer Center), David M. Hyman(Memorial Sloan Kettering Cancer Center), Sujata Patil(Kettering University), Zsofia K. Stadler(Memorial Sloan Kettering Cancer Center), Semanti Mukherjee(Zucker Hillside Hospital), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Liying Zhang(Memorial Sloan Kettering Cancer Center), Kuo‐Cheng Huang(National Institutes of Applied Research), Carolyn Stewart(Memorial Sloan Kettering Cancer Center), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center)
JAMA Oncology
July 6, 2018
Cited by 202


Related Papers